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Background: Pneumocystis pneumonia (PCP) may develop as a clinical manifestation of nosocomial pneumonia by
means of either reactivation of resident P. jirovecii or de novo infection. However, there have been no studies describing
the clinical characteristics of hospital-onset PCP.
Methods: A retrospective review of medical records was performed to identify episodes of hospital-onset PCP in
a tertiary care centre in Korea between May 2007 and January 2013. We investigated whether human-to-human
contact during hospitalisation contributed to PCP development by molecular analysis of the genes encoding
mitochondrial large ribosomal subunit (mtLSU) rRNA and dihydropteroate synthase (DHPS) and a review of
hospitalisation history.
Results: During the study period, 129 patients (130 episodes) were diagnosed with PCP. Of these, respiratory
specimens from 94 patients during 95 PCP episodes were available for analysis. Sixteen episodes (16.8%) were
categorised as hospital-onset PCP. There was a trend toward a higher proportion of haematological malignancy
(43.8% [7/16] vs. 20.3% [16/79]; P = 0.058) in patients with hospital-onset PCP compared to patients with community-
onset PCP. mtLSU genotype 1 was the most common, occurring in 41 (43.2%) patients. There were four possible cases
of nosocomial transmission. Mutation in DHPS was not observed in any PCP episode.
Conclusions: PCP can be one of the causes of nosocomial pneumonia, although the mode of acquisition and
transmission of P. jirovecii remains uncertain. mtLSU genotype 1 is the predominant P. jirovecii strain in Korea.
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Pneumocystis pneumonia (PCP) is a major opportunistic
infection in immunocompromised patients principally ac-
quired and transmitted via an airborne route [1]. It has been
proposed previously that Pneumocystis jirovecii infects the
host during childhood, becomes part of the resident micro-
bial flora and remains latent for extended periods, reactivat-
ing when the host becomes immunocompromised. This* Correspondence: sung@amc.seoul.kr
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unless otherwise stated.theory is based on the observation that most humans
become seropositive for P. jirovecii early in life [2], and
that the colonisation of P. jirovecii in animal models
persists over long periods of time [3]. By contrast, other
researchers suggest that P. jirovecii infects transiently
and that active transmission is possible. This idea is
supported by early clearance of P. jirovecii from the
lungs of adult animals [4] and detection of mutations in
dihydropteroate synthase (DHPS) in human immuno-
deficiency virus (HIV)-infected patients without prior
sulfamethoxazole prophylaxis [5]. Recent reports of clus-
ters or outbreaks of a single genetic strain of P. jiroveciiis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mission [6-10].
Based on these previous observations, PCP may develop
as a clinical manifestation of nosocomial pneumonia by
means of either reactivation of resident P. jirovecii or
de novo infection [11]. Damiani et al. provided additional
data supporting P. jirovecii exhalation by infected patients,
showing that a full match of P. jirovecii genotypes was
found for 4 (57.1%) pairs of pulmonary and room air sam-
ples [7]. Therefore, de novo infection by human-to-human
transmission may be a cause of some of PCP development
during hospitalisation. Thus, it is necessary to apply mea-
sures preventing airborne transmission of P. jirovecii in
hospitals.
In this study, we retrospectively identified the episodes
of hospital-onset PCP. We performed a molecular analysis
of the genes encoding mitochondrial large ribosomal sub-
unit (mtLSU) rRNA and DHPS and a review of hospital-
isation history of patients with PCP to investigate whether
human-to-human contact during hospitalisation contrib-
uted to PCP development.Methods
Ethics statement
This work was approved by the Research Ethics Commit-
tee at Asan Medical Centre, Seoul, Republic of Korea. In-
formed consent was waived by the Institutional Review
Board of Asan Medical Center since this work was a retro-
spective study without intervention and did not involve
extra clinical specimens.Study design and patients
This study was performed at Asan Medical Center, a
2,700-bed tertiary care teaching hospital, from May 1, 2007
to January 31, 2013. The study included patients with
compatible symptoms and radiological findings con-
firmed as PCP by a direct immunofluorescence assay
(Light Diagnostics™ Pneumocystis carinii DFA Kit, Millipore,
Billerica, MA, USA) using respiratory specimens. We
excluded patients whose respiratory specimens were
not available for molecular analysis. Respiratory speci-
mens were not collected between September 1, 2009 and
September 31, 2011 because the principal investigator was
on sabbatical leave. During a retrospective medical review,
we identified episodes of hospital-onset PCP which was
defined as pneumonia arising more than 5 days after
admission when no signs and symptoms compatible with
PCP were documented at the time of admission. The
5 day-cutoff for diagnosing hospital-onset PCP is same
as that used in previous studies of late-onset ventilator-
associated pneumonia [12]. Other patients were consid-
ered to have community-onset PCP.Data collection
The patients’ medical records were reviewed retrospect-
ively, and clinical information was collected, including
demographics, underlying diseases and conditions, hospital-
isation history, reason for admission, signs and symptoms
of PCP, radiological findings, history of prior prophylaxis
against PCP, laboratory findings (neutrophil and lympho-
cyte counts in bronchoalveolar lavage [BAL] fluid, absolute
neutrophil and lymphocyte counts, lactate dehydrogenase,
and C-reactive protein), initial severity of PCP, treatment
regimens and response, need for mechanical ventilation
and 30-day mortality from the time of initial PCP diagnosis.
Using this information, we compared the clinical character-
istics of patients with hospital-onset and community-onset
PCP. A possible case of nosocomial transmission was de-
fined as a patient with a history of admission to the same
ward in which another patient infected with a genetically
identical strain of P. jirovecii, determined by mtLSU and
DHPS sequencing, had stayed.
Genotyping
The majority of specimens (n = 92) were acquired through
from BAL obtained using a fibre-optic bronchoscope and
standard techniques. Three specimens obtained by endo-
tracheal aspiration. We performed a retrospective molecu-
lar analysis of the P. jirovecii mtLSU and DHPS loci. BAL
specimens (350 μl) were treated with proteinase K and
DNA was extracted using QIAamp DNA Stool Mini Kits
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. The single-copy DHPS gene was
amplified by nested PCR using the primers F1 and B45
(first round) and AHUM and BN (second round) in all
positive samples, as described previously [13,14]. mtLSU
rRNA gene was amplified by nested PCR using the primers
pAZ102-E and pAZ102-H (first round) and pAZ102-X and
pAZ102-Y (second round) in all samples, as described pre-
viously [2,15]. Amplicons were purified using a Power
Gel Extraction kit (TaKaRa Bio Inc., Shiga, Japan) and
directly sequenced on an ABI Prism 3130xl genetic ana-
lyser (Applied Biosystems, Foster City, CA, USA) using a
BigDye Terminator v. 3.1 cycle sequencing kit (Applied
Biosystems). DHPS genotypes were as follows: genotype 1,
165A and 171C (resulting in Thr and Pro); genotype 2,
165G and 171C (resulting in Ala and Pro); genotype 3,
165A and 171T (resulting in Thr and Ser); and genotype
4, 165G and 171T (resulting in Ala and Ser). mtLSU geno-
types were as follows: genotype 1 = 85C/248C, 2 = 85A/
248C, 3 = 85T/248C and 4 = 85C/248T [16].
Statistical analyses
Chi-square or Fisher’s exact test was used to compare
categorical variables, and either Student’s t-test or the
Mann–Whitney U-test was used to compare continuous
variables, as appropriate. Data were analysed using SPSS for
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value of P <0.05 was taken to indicate statistical significance.
Results
Identification of hospital-onset PCP
During the study period, a total of 130 PCP episodes were
documented in 129 patients. There were 95 episodes be-
tween May 2007 and August 2009, 54 during the interrup-
tion period, and 35 between October 2011 and January
2013. Of these, adequate specimens for the study were
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Data are numbers (%) of patients, unless otherwise indicated.
*Hospital-onset PCP was defined as pneumonia arising more than 5 days after adm
the time of admission. Other patients were considered to have community-onset P
†Autoimmune haemolytic anaemia and Steven-Johnson’s syndrome in patients with ho
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‡It was checked only in patients with a haematologic malignancy on chemotherapy
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fraction of inspired oxygen after 7 days of therapy.
ALC, absolute lymphocyte count; ANC, absolute neutrophil count; BAL, bronchoalveola
IQR, interquartile range; LDH, lactate dehydrogenase; PCP, Pneumocystis jirovecii pneum(73.7%; out of 95 episodes) obtained between May 2007
and August 2009, and 25 (71.4%; out of 35 episodes)
obtained between October 2011 and January 2013. In
one patient with recurrent episodes, PCP developed in
both June 2008 and April 2009. Sixteen patients were
categorised as having hospital-onset PCP (Table 1). At
the time of admission, none of the patients had signs or
symptoms compatible with PCP, and all were admitted
as a result of problems not associated with the respiratory
system. The median number of days from admission to
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community-onset PCP
Malignancy and transplantation were common under-
lying diseases and conditions. All patients with connect-
ive tissue disease or interstitial lung disease were on
immunosuppression. Trimethoprim/sulfamethoxazole was
chosen as the initial regimen in almost all patients. Among
these patients, 30.5% (29/95) failed to respond to the ini-
tial therapy. The 30-day all-cause mortality rate was 26.3%
(25/95). A comparison of the clinical characteristics of
patients with hospital-onset and community-onset PCP
demonstrated no statistically significant differences (Table 1)
except a trend toward a higher proportion of haemato-
logical malignancy as an underlying disease (hospital-onset
PCP, 43.8% [7/16] vs. community-onset, 20.3% [16/79];
P = 0.058) and a higher 30-day mortality in patients with
PCP developing during hospitalisation (hospital-onset
PCP, 43.8% [7/16] vs. community-onset, 22.8% [18/79];
P = 0.12). To adjust for a possible confounding effect on
outcome, we performed a subgroup analysis of patients
with haematological malignancy. There was no statistically
significant difference between the groups, possibly due
to the small number of patients (hospital-onset PCP,
3/7 [42.9%] vs. community-onset, 2/16 [12.5%]; P = 0.14).
Possible nosocomial transmission of P. jirovecii
We identified four possible cases of nosocomial transmis-
sion (Figure 1). Of these, three patients with hospital-
onset PCP with mtLSU genotype 1 strains (patients 49, 58,Figure 1 A transmission map for patients with Pneumocystis pneumo
(mtLSU) rRNA genotypes. Genotypes were determined by direct sequenc
3 = 85T/248C, and 4 = 85C/248T. Patients 49, 58, and 66 with genotype 1 st
the same room. Patient 65, who developed hospital-onset PCP with a mixe
had a strain with the same mixed genotype was hospitalised. Patients 56 aand 66) stayed in ward 74 during a similar period, al-
though they did not share the same room (Figure 2). It
was unclear who might be an index patient among them.
Patient 65, who developed hospital-onset PCP with a
mixed mtLSU genotype 1, 2 , stayed in ward 174, where
patient 56 who had a strain with the same mixed genotype
was hospitalised. Patients 56 and 65 also did not share the
same room (Figure 2).
Genotype distribution of P. jirovecii
Genotype results of strains from all episodes, analysed
by mtLSU and DHPS sequencing, are summarised in
Table 2. mtLSU genotype 1 was the most common, oc-
curring in 41 (43.2%) cases, followed by type 3 in 21
(22.1%) cases. Only one episode with genotype 4 was iden-
tified. Strains with mixed genotypes were found in 27 epi-
sodes (28.4%). In the patient with recurrent episodes, a
mixture of genotypes 2 and 3 was identified in both
episodes. DHPS mutation was not observed in any epi-
sode. Nine of thirteen episodes in HIV-infected patients
were with genotype 1, which was a higher proportion
than in non-HIV-infected patients (HIV, 69.2% [9/13] vs.
non-HIV, 37.8% [31/82]; P = 0.04).
Discussion
In the present study, a significant proportion of PCP
cases developed as a clinical manifestation of nosocomial
pneumonia. We found a trend toward a higher proportion
of haematological malignancy in patients with hospital- 
 
nia (PCP) based on mitochondrial large ribosomal subunit
ing of nucleotides 85 and 248: genotype 1 = 85C/248C, 2 = 85A/248C,
ayed in ward 74 during a similar period, although they did not share
d mtLSU genotype 1, 2 , stayed in ward 174, in which patient 56 who
nd 65 also did not share the same room
Figure 2 A transmission map for possible cases of nosocomial transmission of Pneumocystis jirovecii. Genotypes of the mitochondrial
large ribosomal subunit (mtLSU) were determined by direct sequencing of nucleotides 85 and 248: genotype 1 = 85C/248C, 2 = 85A/248C,
3 = 85T/248C, and 4 = 85C/248T. A dark grey box indicates the period of hospitalisation during the PCP episode. The thick vertical line is the
time when hospital-onset PCP was diagnosed. Patients 49, 58, and 66 stayed in ward 74 during a similar period. Patients 56 and 65 stayed in
ward 174 during the same period. No., case number; Hospital-onset PCP marked by a black box; M1, the first medical intensive care unit; M2,
second medical intensive care unit; W, ward
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isation period during chemotherapy. This finding indi-
cates that PCP should be considered in the differential
diagnosis of nosocomial pneumonia and that the list of
differential diagnosises was heavily dependent on the im-
mune status and clinical characteristics. mtLSU genotype
1 was the most common P. jirovecii strain in Korea. We
did not identify an association of any particular genetic
strain with hospital-onset PCP. Thus, the impact of geno-
type on the occurrence of hospital-onset PCP and clinical
outcomes should be further investigated.
Several studies have suggested that PCP results from
de novo infection by nosocomial transmission, rather than
from reactivation of latent infection. Clustering or out-
break strains with the same genotypes determined by
various molecular methods suggest that P. jirovecii can
be acquired by human-to-human transmission [6-10,17-19].
Additionally, recent studies suggest that the hospital
environment and patients colonised with P. jirovecii
can be a source of transmission [7,20]. Unlike these previ-





1 85C/248C 41 (4
2 85A/248C 5 (5.2
3 85T/248C 21 (2
4 85C/248T 1 (1.0
Mixed (total) 27 (2
1 and 2 13 (1
1 and 3 11 (1
2 and 3 3 (3.1contributed to PCP development during outbreak or clus-
ters, the present study investigated the possibility of noso-
comial transmission during the period without outbreak
or clusters. Our findings also suggest human-to-human
transmission to be a possible mode of P. jirovecii acquisi-
tion in hospitalised patients. Based on these results, pa-
tients with PCP may need to be isolated to prevent
human-to-human transmission, and universal surveillance
for PCP colonisation may be necessary before admission
to wards containing immunocompromised patients. How-
ever, these results should be interpreted with caution
before they are applied to a strategy for PCP prevention.
First, in the present study, most of the patients with
hospital-onset PCP had no history of possible nosoco-
mial transmission. This suggests that the de novo acqui-
sition of P. jirovecii, at least, may rarely occur during
hospitalisation. Second, no DHPS mutations were found
despite a prior history of exposure to sulfamethoxazole in
many patients. In a previous study, DHPS mutations were
not detected in patients in whom PCP developed prior
to the widespread use of sulfamethoxazole to treat and) genotypes in patients with P. jirovecii pneumonia
DHPS
(%) Nucleotide position/identity No. (%)
3.2) 165 (55)/A (Thr); 171 (57)/C (Pro) 95 (100)
) 165 (55)/G (Ala); 171 (57)/C (Pro) 0 (0.0)
2.1) 165 (55)/A (Thr); 171 (57)/T (Ser) 0 (0.0)
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hospital-onset PCP may be infected from reservoir pop-
ulations in the community that have not been exposed
to sulfamethoxazole. Additionally, the genotype distribu-
tions were not different between patients with hospital-
onset and community-onset PCP developing. Finally,
owing to the long incubation period of P. jirovecii [21],
it was impossible to strictly differentiate between de
novo acquisition and reactivation. Therefore, the mode
of acquisition and transmission of P. jirovecii causing
pneumonia during hospitalisation could not be deter-
mined in the present study.
The genetic epidemiological features identified in this
study determined that the mtLSU genotype 1 was the
predominant P. jirovecii strain, there was a high prevalence
of mixed-genotype strains, and DHPS mutations were ab-
sent. In previous studies in Spain and Japan, genotype 1
was also the most common, occurring in 30% and 49% of
patients, respectively, which is comparable to the present
study [16,22]. By contrast, genotypes 2 and 3 were reported
to be the most prevalent strains in India [23] and Tunisia
[24], respectively. In addition, a significant prevalence
of mutations in DHPS (20–37%) was reported in several
countries [16,23-25], while only one DHPS mutant was
found among 52 strains in Japan [22]. These variable
genetic epidemiological findings may be due to geograph-
ical differences. We found that genotype 1 occurred more
frequently in HIV-infected patients compared to non-
HIV-infected patients, which is similar to the report by
Montes-Cano et al. [16].
The 30-day all-cause mortality rate was 26.3%. This high
rate seems to be associated with the high proportion of
patients with a non-haematologic malignancy and intersti-
tial lung disease [26]. The rate of treatment failure in the
initial therapy was similar to that in our previous study
[27]. Our group has already published a number of articles
on various clinical issues related to PCP, including the effi-
cacy of salvage therapy regimens and the role of adjunctive
corticosteroids [27,28]. Therefore, clinical issues were not
extensively reviewed in the present study.
The present study had several limitations. First, because
the incubation period of P. jirovecii is quite broad (range,
7–188 days) [21], 5 days may not be an appropriate cut-off
for differentiating between cases of hospital-acquired and
community-acquired PCP. Therefore, we have applied
the terms ‘hospital-onset’ and ‘community-onset’ rather
than ‘hospital-acquired’ and ‘community-acquired’ PCP.
Second, a significant number of patients with PCP
(36.9%, 35/130) were not included in the molecular ana-
lysis due to a lack of suitable specimens. Third, DHPS and
mtLSU genotyping may not be optimal for epidemio-
logical investigations. To get better discriminatory power,
other molecular methods such as multilocus sequence
typing should be done [29]. Fourth, other sources ofnosocomial transmission, such as patient-to-patient trans-
mission in other hospital departments and the acquisition
of P. jirovecii from other hospital environments, were not
investigated. Moreover, we did not search for P. jirovecii-
infected individuals without definite signs and symptoms,
who can act as problematic reservoirs. Finally, generalisa-
tions cannot be made from this study, as it was conducted
in a single centre. Different conclusions may result from
studies of other populations.
Conclusions
In conclusion, some episodes of PCP develop as nosoco-
mial pneumonia. PCP should be considered as one of the
causes of nosocomial pneumonia in immunocompromised
patients, such as those with haematological malignancy.
Molecular analysis of mtLSU rRNA indicated that a strain
of genotype 1 was predominant in Korea. Further investi-
gation should be performed to identify the mode of acqui-
sition and transmission of P. jirovecii causing pneumonia
during hospitalisation.
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